Mucormycosis: its contemporary face and management strategies

被引：107

作者：

Sun, Hsin-Yun ^{[1
,2
,3
]}

Singh, Nina ^{[1
,4
]}

机构：

[1] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA USA

[2] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan

[3] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan

[4] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA USA

来源：

LANCET INFECTIOUS DISEASES | 2011年 / 11卷 / 04期

关键词：

LIPOSOMAL AMPHOTERICIN-B; ORGAN TRANSPLANT RECIPIENTS; INVASIVE FUNGAL-INFECTIONS; CALCINEURIN-INHIBITOR AGENTS; STEM-CELL TRANSPLANTATION; COLONY-STIMULATING FACTOR; LIPID COMPLEX; IN-VITRO; HYPERBARIC-OXYGEN; BREAKTHROUGH ZYGOMYCOSIS;

D O I：

10.1016/S1473-3099(10)70316-9

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Several countries have seen rising frequencies of mucormycosis among patients with haematological disorders, malignancies, or diabetes mellitus, and among transplant recipients. Growing numbers of immunocompromised hosts, widespread use of antifungal agents inactive against mucormycosis, or other unidentified factors, could be contributing to this situation. The predominant clinical manifestations of mucormycosis vary from host to host. Additionally, risk factors specific to different subgroups have been identified, such as leukaemia, allogeneic haemopoietic stem-cell transplant, voriconazole prophylaxis, diabetes, and malnutrition. We summarise the current state of knowledge of characteristics and risk factors and discuss topical developments in therapeutic methods and strategies in the management of mucormycosis.

引用

页码：301 / 311

页数：11

共 137 条

[91] Forty-one recent cases of invasive zygomycosis from a global clinical registry [J].

Rueping, M. J. G. T. ;

Heinz, W. J. ;

Kindo, A. J. ;

Rickerts, V. ;

Lass-Floerl, C. ;

Beisel, C. ;

Herbrecht, R. ;

Roth, Y. ;

Silling, G. ;

Ullmann, A. J. ;

Borchert, K. ;

Egerer, G. ;

Maertens, J. ;

Maschmeyer, G. ;

Simon, A. ;

Wattad, M. ;

Fischer, G. ;

Vehreschild, J. J. ;

Cornely, O. A. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (02) :296-302

[92] Patients at High Risk of Invasive Fungal Infections When and How to Treat [J].

Rueping, Maria J. G. T. ;

Vehreschild, Joerg J. ;

Cornely, Oliver A. .

DRUGS, 2008, 68 (14) :1941-1962

[93] Antifungal treatment strategies in high risk patients [J].

Rueping, Maria J. G. T. ;

Vehreschild, Joerg J. ;

Cornely, Oliver A. .

MYCOSES, 2008, 51 :46-51

[94] Antifungal immunity and adjuvant cytokine immune enhancement in cancer patients with invasive fungal infections [J].

Safdar, A. .

CLINICAL MICROBIOLOGY AND INFECTION, 2007, 13 (01) :1-4

[95] Renal impairment and Amphotericin B formulations in patients with invasive fungal infections [J].

Saliba, Faouzi ;

Dupont, Bertrand .

MEDICAL MYCOLOGY, 2008, 46 (02) :97-112

[96] Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation [J].

Schlemmer, F. ;

Lagrange-Xelot, M. ;

Lacroix, C. ;

de La Tour, R. ;

Socie, G. ;

Molina, J-M .

BONE MARROW TRANSPLANTATION, 2008, 42 (08) :551-552

[97] ANTIFUNGAL PROPERTIES OF POLYMYXIN-B AND ITS POTENTIATION OF TETRACYCLINE AS AN ANTIFUNGAL AGENT [J].

SCHWARTZ, SN ;

SCHLESSINGER, D ;

MEDOFF, G ;

KOBAYASHI, GS ;

KWAN, CN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1972, 2 (01) :36-+

[98]

Segal E, 2007, ISRAEL MED ASSOC J, V9, P355

[99] Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases [J].

Shoham, Shmuel ;

Magill, Shelley S. ;

Merz, William G. ;

Gonzalez, Corina ;

Seibel, Nita ;

Buchanan, Wendy L. ;

Knudsen, Tena A. ;

Sarkisova, Tatyana A. ;

Walsh, Thomas J. .

MEDICAL MYCOLOGY, 2010, 48 (03) :511-517

[100] Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes [J].

Simitsopoulou, Maria ;

Roilides, Emmanuel ;

Maloukou, Avgi ;

Gil-Lamaignere, Cristina ;

Walsh, Thomas J. .

MYCOSES, 2008, 51 (02) :147-154

← 5 6 7 8 9 10 11 12 13 14 →